Niagen Board Member Gets $280K Stock Option Package in Latest Compensation Deal

Rhea-AI Filing Summary

Form 4 filing reveals that Ann Cohen, Director at Niagen Bioscience, was granted stock options on June 24, 2025. Key details of the transaction:

• Received 20,000 stock options to purchase common stock
• Exercise price set at $14.13 per share
• Options will vest 100% on June 24, 2026
• Options expire on June 23, 2035
• Direct ownership form of securities

This grant represents a standard director compensation package, with a one-year cliff vesting schedule. The filing was signed by James Lee as attorney-in-fact on June 25, 2025. No other securities transactions were reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cohen Ann

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 20,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Ann

(Last) (First) (Middle)

10900 WILSHIRE BLVD. SUITE 600

(Street)

LOS ANGELES CA 90024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.13	06/24/2025		A		20,000		06/24/2026(1)	06/23/2035	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Option vests 100% on June 24, 2026.

Remarks:

	/s/ Jeong James Lee, Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did NAGE director Ann Cohen receive on June 24, 2025?

Ann Cohen received 20,000 stock options with an exercise price of $14.13. These options were granted on June 24, 2025, and have an expiration date of June 23, 2035.

When do Ann Cohen's NAGE stock options vest?

According to the Form 4 filing, the stock options vest 100% on June 24, 2026, one year after the grant date.

What is the exercise price of NAGE stock options granted to director Ann Cohen?

The stock options were granted with an exercise price of $14.13 per share.

Who filed the Form 4 for NAGE director Ann Cohen?

The Form 4 was signed by Jeong James Lee as Attorney-in-Fact on June 25, 2025, on behalf of Ann Cohen.

What position does Ann Cohen hold at NAGE (Niagen Bioscience)?

According to the Form 4 filing, Ann Cohen serves as a Director of Niagen Bioscience, Inc. (NAGE). The filing indicates she is not an officer or 10% owner of the company.